Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7341-7347

  Dome, Balazs ^a,b,d   Timar, Jozsef ^a,b   Dobos, Judit ^a,b   Meszaros, Livia ^b   Raso, Erzsebet ^b   Paku, Sandor ^c   Kenessey, Istvan ^b   Ostoros, Gyula ^a   Magyar, Melinda ^a   Ladanyi, Andrea ^b   Bogos, Krisztina ^a   Tovari, Jozsef ^b  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d National Institute of Pulmonology   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CD133 ANTIGEN; CD34 ANTIGEN; MESSENGER RNA; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

ANTIGENS, CD; ANTIGENS, CD34; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33746906996     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4654     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003;22:6629-38.
3. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-56.
4. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004;10:4258-62s.
5. Pastorino V, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
6. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;15:2456-66.
7. Chandrachud LM, Pendleton N, Chisholm DM, et al. Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer 1997;76:1367-75.
8. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of valuation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-79.
9. Timar J, Dome B, Fazekas K, et al. Angiogenesis-dependent diseases and angiogenesis therapy. Pathol Oncol Res 2001;7:85-94.
10. Davidoff AM, Ng CY, Brown P, et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001;7:2870-9.
11. Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 2002;8:3622-7.
12. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004;57:965-9.
13. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-42.
14. Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005;112:1618-27.
15. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med 2003;13:201-6.
16. Mountain FC. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
17. Sussman LK, Upalakalin JN, Roberts MJ, et al. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol Ther 2003;2:255-6.
18. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
19. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005;45:1449-57.
20. Adams V, Lenk K, Linke A, et al. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol 2004;24:684-90.
21. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004;109:220-6.
22. Natori T, Sata M, Washida M, et al. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2002;297:1058-61.
23. +, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:5688-95.
24. Cortelezzi A, Fracchiolla NS, Mazzeo LM, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma 2005;46:1345-51.
25. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005;11:261-2.
26. Ellis LM. Bevacizumab. Nat Rev Drug Discov 2005;Suppl:S8-9.
27. Schneider M, Tjwa M, Carmeliet P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005;7:3-4.
28. Miller JC, Pien HH, Sahani D, et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172-87.
29. Shaked Y, Emmenegger U Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.
30. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9.
31. Treat J. Incorporating novel agents with gemcitabine-based treatment of NSCLC. Lung Cancer 2005;50S1:S8-9.
32. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
33. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
34. Rabascio C, Muratori E, Mancuso P, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004;64:4373-7.
35. Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
36. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-1 and VEGF-R2-1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999;188:369-77.
37. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550-63.
38. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
39. O'Neill TJ IV, Wamhoff BR, Owens GK, et al. Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ Res 2005;97:1027-35.